Martina Porter, MD, discusses long-term results from the phase 3 STOP-HS program evaluating povorcitinib in patients with hidradenitis suppurativa.
Martina Porter, MD
Advertisement
Martina Porter, MD, vice chair of research, Beth Israel Deaconess Medical Center, Harvard Medical School.
Articles by Martina Porter, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
How Often Do Health Insurers Deny Doctor-Recommended Care?
2
Acoramidis Shows Durable Benefit at 54 Months in ATTR-CM
3
New Data Support Pimicotinib as Durable for Rare Tenosynovial Giant Cell Tumor
4
What Managed Care Should Watch at ADA 2026 Scientific Sessions
5